Novartis Investigative Site

Sugar Land, Texas 77479

0 studies enrolling now · 8 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease and Lipoprotein(a), Diabetes Mellitus and Heart Failure, Diabetic Nephropathy, Multiple Sclerosis, Plaque Psoriasis, Psoriasis, Rheumatoid Arthritis

Studies at this site

• Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) — Completed